Considering both butyrylcholinesterase inhibition activity and neuroprotective properties of tegaserod that have been shown in the present work, the repurposing of this 5-HT4R agonist should be a valuable option for AD treatment. This evidence concerns the gene BCHE and Alzheimer disease.